Eli Lilly and Company (LLY) Expands U.S. Manufacturing and Advances Breakthrough Therapies

Eli Lilly and Company (NYSE:LLY) is one of the best healthcare stocks to buy for 2026. On January 29, Reuters reported that U.S. President Donald Trump said Eli Lilly plans to build six new manufacturing plants in the United States. Lilly previously announced it would invest at least $27 billion to expand production and strengthen medical supply chains, with four plants planned and three already confirmed in Alabama, Virginia, and Texas. The expansion aims to boost U.S. manufacturing capacity and support the company’s long-term growth in pharmaceuticals.

On January 20, the US Food and Drug Administration granted Eli Lilly and Company Breakthrough Therapy Designation for its ovarian cancer drug sofetabart mipitecan. The designation paves the way for expedited development and review of the drug as it targets a serious condition.

The company secured the breakthrough designation following a positive Phase 1a/b STUDY. The results showed responses at all dose levels and across all folate receptor alpha expression levels, including patients on mirvetuximab soravtansine. The trial results also showed low rates of intestinal lung disease, peripheral neuropathy, and alopecia. ‘

Sofetabart mipitecan is currently in a Phase 3 Framework-01 study investigating its effectiveness as a monotherapy in patients with platinum-resistant ovarian cancer. Eli Lilly is investigating the drug in partnership with the European Network for Gynecological Oncological Trial Groups .

Meanwhile, Bernstein has reiterated an Outperform rating on Eli Lilly, set a $1300 price target, and touted it as a top pick in the sector. The positive stance comes as the research firm expects the company to capitalize on the oral medication opportunity and international expansion. The company should also benefit from its push to expand its diabetes treatment opportunities.

Eli Lilly and Company (NYSE:LLY) is a global healthcare company that discovers, develops, manufactures, and markets pharmaceutical products, focusing on diabetes (including insulin), oncology, immunology, neurodegeneration, and pain.

While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 12 Best Consumer Goods Stocks Billionaires Are Quietly Buying and Goldman Sachs Penny Stocks: Top 12 Stock Picks.

Disclosure: None. This article is originally published at Insider Monkey.